These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 25066302)

  • 1. Enhanced brain distribution of modified aspartoacylase.
    Poddar NK; Zano S; Natarajan R; Yamamoto B; Viola RE
    Mol Genet Metab; 2014 Nov; 113(3):219-24. PubMed ID: 25066302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modification of aspartoacylase for potential use in enzyme replacement therapy for the treatment of Canavan disease.
    Zano S; Malik R; Szucs S; Matalon R; Viola RE
    Mol Genet Metab; 2011 Feb; 102(2):176-80. PubMed ID: 21095151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uncoupling N-acetylaspartate from brain pathology: implications for Canavan disease gene therapy.
    von Jonquieres G; Spencer ZHT; Rowlands BD; Klugmann CB; Bongers A; Harasta AE; Parley KE; Cederholm J; Teahan O; Pickford R; Delerue F; Ittner LM; Fröhlich D; McLean CA; Don AS; Schneider M; Housley GD; Rae CD; Klugmann M
    Acta Neuropathol; 2018 Jan; 135(1):95-113. PubMed ID: 29116375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aspartoacylase is restricted primarily to myelin synthesizing cells in the CNS: therapeutic implications for Canavan disease.
    Kirmani BF; Jacobowitz DM; Kallarakal AT; Namboodiri MA
    Brain Res Mol Brain Res; 2002 Nov; 107(2):176-82. PubMed ID: 12487123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of human aspartoacylase: the brain enzyme responsible for Canavan disease.
    Le Coq J; An HJ; Lebrilla C; Viola RE
    Biochemistry; 2006 May; 45(18):5878-84. PubMed ID: 16669630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-acetylaspartate supports the energetic demands of developmental myelination via oligodendroglial aspartoacylase.
    Francis JS; Wojtas I; Markov V; Gray SJ; McCown TJ; Samulski RJ; Bilaniuk LT; Wang DJ; De Vivo DC; Janson CG; Leone P
    Neurobiol Dis; 2016 Dec; 96():323-334. PubMed ID: 27717881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutational analysis of aspartoacylase: implications for Canavan disease.
    Hershfield JR; Pattabiraman N; Madhavarao CN; Namboodiri MA
    Brain Res; 2007 May; 1148():1-14. PubMed ID: 17391648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cloning of the human aspartoacylase cDNA and a common missense mutation in Canavan disease.
    Kaul R; Gao GP; Balamurugan K; Matalon R
    Nat Genet; 1993 Oct; 5(2):118-23. PubMed ID: 8252036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between enzyme properties and disease progression in Canavan disease.
    Zano S; Wijayasinghe YS; Malik R; Smith J; Viola RE
    J Inherit Metab Dis; 2013 Jan; 36(1):1-6. PubMed ID: 22850825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reexamination of aspartoacylase: is this human enzyme really a glycoprotein?
    Wang Q; Viola RE
    Arch Biochem Biophys; 2014 Apr; 548():66-73. PubMed ID: 24632142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel aspartoacylase (ASPA) gene mutation in Canavan disease.
    Durmaz AA; Akin H; Onay H; Vahabi A; Ozkinay F
    Fetal Pediatr Pathol; 2012 Aug; 31(4):236-9. PubMed ID: 22468686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brain Nat8l Knockdown Suppresses Spongiform Leukodystrophy in an Aspartoacylase-Deficient Canavan Disease Mouse Model.
    Bannerman P; Guo F; Chechneva O; Burns T; Zhu X; Wang Y; Kim B; Singhal NK; McDonough JA; Pleasure D
    Mol Ther; 2018 Mar; 26(3):793-800. PubMed ID: 29456021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and distribution of aspartoacylase in the postnatal rat brain.
    Klugmann M; Symes CW; Klaussner BK; Leichtlein CB; Serikawa T; Young D; During MJ
    Neuroreport; 2003 Oct; 14(14):1837-40. PubMed ID: 14534431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Developmental increase of aspartoacylase in oligodendrocytes parallels CNS myelination.
    Kirmani BF; Jacobowitz DM; Namboodiri MA
    Brain Res Dev Brain Res; 2003 Jan; 140(1):105-15. PubMed ID: 12524181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain.
    Janson C; McPhee S; Bilaniuk L; Haselgrove J; Testaiuti M; Freese A; Wang DJ; Shera D; Hurh P; Rupin J; Saslow E; Goldfarb O; Goldberg M; Larijani G; Sharrar W; Liouterman L; Camp A; Kolodny E; Samulski J; Leone P
    Hum Gene Ther; 2002 Jul; 13(11):1391-412. PubMed ID: 12162821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel mutation of aspartoacylase gene in a Turkish patient with Canavan disease.
    Unalp A; Altiok E; Uran N; Oztürk A; Yüksel S
    J Trop Pediatr; 2008 Jun; 54(3):208-10. PubMed ID: 17999961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Purification and preliminary characterization of brain aspartoacylase.
    Moore RA; Le Coq J; Faehnle CR; Viola RE
    Arch Biochem Biophys; 2003 May; 413(1):1-8. PubMed ID: 12706335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Purification, characterization, and localization of aspartoacylase from bovine brain.
    Kaul R; Casanova J; Johnson AB; Tang P; Matalon R
    J Neurochem; 1991 Jan; 56(1):129-35. PubMed ID: 1987315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A mutation of aspartoacylase gene in a Turkish patient with Canavan disease.
    Eke GH; Iscan A; Cece H; Calik M
    Genet Couns; 2012; 23(1):9-12. PubMed ID: 22611636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural modeling of p.V31F variant in the aspartoacylase gene.
    Krishnamoorthy N; Zayed H
    Metab Brain Dis; 2016 Jun; 31(3):723-6. PubMed ID: 26797702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.